DoW Breast Cancer, Clinical Research Extension Award
Grant Opportunity Analysis
The Defense Health Agency Contracting Activity is seeking applications for the Fiscal Year 2026 Breast Cancer Research Program Clinical Research Extension Award to support research that extends data collection, patient follow-up, and analysis of existing breast cancer clinical trials. Funded projects must maximize the impact of patient-contributed biospecimens and clinical data, prevent the loss of scientific knowledge, and address at least one program-defined overarching breast cancer challenge without initiating new clinical trials or enrolling new patients. The performance period is a maximum of four years, and the research team must include at least two breast cancer consumer advocates. Applicants may propose a single Principal Investigator or utilize a Partnering PI Option, with total funding capped at $7.0 million or $8.4 million respectively. A pre-application Letter of Intent must be submitted through eBRAP by November 4, 2026, followed by a full application due by November 18, 2026.